Considerations for the design and conduct of a pharmacovigilance study involving mass drug administration in a resource-constrained setting.
Alemayehu
Demissie
D
Clinical Affairs, Pfizer, New York, New York, United States of America.
Andrews
Emma N
EN
Glue
Paul
P
Knirsch
Charles A
CA
D016907:Adverse Drug Reaction Reporting Systems; D000871:Anthelmintics / Q000627:therapeutic use; D000977:Antiparasitic Agents / Q000627:therapeutic use; D003140:Communicable Disease Control / Q000379:methods; D004605:Elephantiasis, Filarial / Q000188:drug therapy; D006373:Helminthiasis / Q000188:drug therapy; D006801:Humans; D009855:Onchocerciasis / Q000188:drug therapy; D012552:Schistosomiasis / Q000188:drug therapy; D014141:Trachoma / Q000188:drug therapy; D014330:Tropical Medicine / Q000379:methods
D000871:Anthelmintics; D000977:Antiparasitic Agents